News
Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases
Novel approach to treat neurodegenerative diseases by targeting fibrin-driven neuroinflammation was well-tolerated among healthy volunteers, with a clean hematological profile Half-life supports once-monthly dosing Data to be presented at AAIC 25 Sacramento, April 29,...
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
THN391 demonstrated effectiveness in protecting against vascular and neuronal degeneration - Therini Bio plans to initiate a Phase 1/2a trial evaluating THN391 in DME in 2H24 - The data was presented at ARVO 2024 - Sacramento, May 8, 2024 (GLOBE NEWSWIRE) —...
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
- THN391 was found to be safe and well-tolerated - - THN391 demonstrated a prolonged half-life and dose proportional Cmax levels - - The data will be presented October 25-27th at CTAD 2023 - Sacramento, October 24, 2023 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a...
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
- Industry Veteran Frank D. Lee Appointed as Executive Chairperson of the Board SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and...
Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
- Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Therini Bio, Inc., a biotech company aimed at developing fibrin-targeted...
Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
SOUTH SAN FRANCISCO, Calif, May 10, 2021 /PRNewswire/ -- Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing. The capital will accelerate the development of Therini's lead program – a monoclonal antibody against fibrin –...
MedaRed Announces Name Change to Therini Bio
Corporate Headquarters Relocated to Lilly Gateway Labs in South San FranciscoNEWS PROVIDED BYTherini Bio, Inc.Feb 24, 2020, 08:17 ET SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 /PRNewswire/ -- MedaRed, Inc., a vascular biology company focused initially on discovering...
MedaRed Raises $6.5 Million and Appoints Industry Leaders to Board of Directors, Top Management Roles
Daniel Burgess and Jeffrey Stavenhagen, PhD join leadership team NEWS PROVIDED BY MedaRed, Inc.Jul 08, 2019, 08:00 ET SAN FRANCISCO, July 8, 2019 /PRNewswire/ -- MedaRed, Inc., a biotechnology company focused on discovering and developing new therapeutics targeting...
